Shanghai Reinovax Biologics Co., Ltd.

Shanghai Reinovax Biologics Co., Ltd., (Reinovax) is a clinical stage biotech company focusing on discovery and development of innovative vaccines and recombinant protein-based biologics. The company has established a well sophisticated research platform as well as the capability for pilot scale process development and GMP manufacturing via its wholly own subsidiaries. The world’s first 24-valent pneumococcal polysaccharide conjugate vaccine with dual carrier protein by Reinovax has nearly completed the phase II trial for adults and is expected to start the phase III trial in 2025.   

Shanghai Microdom Biotech Co., Ltd.

Shanghai Microdom Biotech Co., Ltd. was established in Lingang Shanghai in March 2021, and is a wholly owned subsidiary of Shanghai Reinovax Biologics Co., Ltd. The company has the capacity for pilot-scale process development and manufacturing of clinical samples for Phase I-III trials.

Shanghai Microdom Biologics Co., Ltd. has a construction area of 5,025 square meters. The GMP-like workshop is equipped with various independent production lines for recombinant proteins, polysaccharides, adjuvants, conjugates, filling and packaging as well as analytical instruments.

Changchun Reinovax Biologics Co., Ltd.

Changchun Reinovax Biologics Co., Ltd. is a wholly owned subsidiary of Shanghai Reinovax Biologics Co., Ltd., with a focus on the commercial scale GMP manufacturing of polyvalent vaccines compliant with domestic, EU or WHO international standards. The company is located in the Biopharma Industry Park of Changchun High-tech Zone, Changchun, Jilin Province, with a construction area of approximately 77,600 square meters.

The manufacturing site has completed the construction and installation of equipment and instruments for all manufacturing suites, analytical laboratory, animal facility, warehouse, waste management, and office building. The validation process is currently ongoing.